Research
Hormonal
Certain environmental chemicals (obesogens and diabetogens) can disrupt metabolic homeostasis by acting on nuclear receptors involved in adipogenesis and insulin sensitivity.
Minimize exposure to known environmental chemicals like BPA (found in some plastics) and certain pesticides where possible. While complete avoidance is difficult, reducing exposure may lower the burden on metabolic pathways regulated by nuclear receptors.
ModerateSupportsMEDIUM confidence
Adipose pathways involving nuclear receptors, such as the estrogen receptor (ER), retinoid X receptor (RXR), peroxisome proliferator-activated receptor-g (PPAR-g), and gluco corticoid receptors (GR), provided some of the first proposed molecular targets of environmental obesogens.
Why this rating
Strong mechanistic data in animal/cell models, but human epidemiological evidence is mixed or inconsistent for many chemicals.
Source
Do Interactions Between Gut Ecology and Environmental Chemicals Contribute to Obesity and Diabetes?
Suzanne M. Snedeker et al. · Environmental Health Perspectives · 2011
DOI 10.1289/ehp.1104204
narrative_reviewCited 183×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Gut microbiota composition influences obesity and diabetes risk through mechanisms including energy harvesting, regulation of fat storage, and induction of metabolic endotoxemia.Good
- Variations in gut microbiota composition affect the absorption, distribution, metabolism, and excretion (ADME) of environmental chemicals, thereby altering individual exposure to obesogenic and diabetogenic toxins.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →